Analysis of data from Israel’s vaccination campaign also showed vaccine to be 94 percent effective against asymptomatic disease
FRIDAY, March 12, 2021 (HealthDay News) — The Pfizer COVID-19 vaccine is 97 percent effective in preventing symptomatic disease in actual use, which is better than previously thought.
The analysis of data gathered from Jan. 17 to March 6 from Israel’s vaccination campaign also showed that the vaccine is 94 percent effective against asymptomatic disease, CBS News reported.
“We are extremely encouraged that the real-world effectiveness data coming from Israel are confirming the high efficacy demonstrated in our phase 3 clinical trial and showing the significant impact of the vaccine in preventing severe disease and deaths due to COVID-19,” said Luis Jodar, Ph.D., senior vice president and chief medical officer of Pfizer Vaccines.
A previous real-world study revealed that the vaccine was 94 percent effective against symptomatic disease and 92 percent effective against asymptomatic disease, CBS News reported.
Nearly 3 in 4 Older Adults Express Interest in Vaccine to Prevent Dementia 
Updated COVID-19 Shot Beneficial for Those With Autoimmune Rheumatic Disease 
AAP Issues Recommendations for Pediatric RSV Vaccination in 2026-2027 Season 
Trends Reported in Vaccination Coverage for Adolescents for 2025 
Nutritional Deficiencies Seen in Youth Taking GLP-1 Receptor Agonists 
Youth Suicide Risk Linked to Community Firearm Violence 
Social Media Warnings Could Discourage Use Among Teens, Young Adults 
Digital Behavioral Health Game Reduces Depressive Symptoms in Teens 
.jpg)
